Departmental Bulletin Paper 転移性淡明腎細胞癌に対する分子標的薬の効果と予後因子の検討
Prognostic Factors and Efficacy of Molecular Targeted Therapy for Metastatic Clear Cell Renal Cell Carcinoma

井上, 隆太  ,  北村, 寛  ,  進藤, 哲哉  ,  柳瀬, 雅裕  ,  高橋, 敦  ,  宮尾, 則臣  ,  伊藤, 直樹  ,  堀田, 裕  ,  広瀬, 崇興  ,  田口, 圭介  ,  松川, 雅則  ,  上原, 央久  ,  国島, 康晴  ,  堀田, 浩貴  ,  舛森, 直哉

61 ( 4 )  , pp.135 - 139 , 2015-04 , 泌尿器科紀要刊行会
We retrospectively reviewed the medical records of patients with metastatic clear cell renal cell carcinoma who received molecular targeted therapy between 2005 and 2011. Cancer-specific survival was analyzed using the Kaplan-Meier method. Predictors of cancer-specific survival were analyzed using the Cox regression hazards model. A total of 89 patients, consisting of 50 first line patients and 39 patients receiving prior cytokine were included in the analysis. The two-year cancer-specific survival rate of the firstlinegroup was 60.2% and that of theprior cytokinethe rapy group was 62.1%. In univariateanalysis, Karnofsky performance status (KPS) <80%, time from diagnosis to treatment less than one year, bone metastasis and C-reactive protein (CRP) >1.3 mg/dl in were statistically significant prognostic factors (p<0.05). In multivariate analysis, time from diagnosis to treatment less than one year (HR 2.46, 95%CI 1.11-5.82, p=0.025) and CRP (HR 4.92, 95%CI 2.23-11.3, p<0.001) were independent prognostic factors. Time from diagnosis to treatment less than one year and CRP were independent prognostic factors in patients who received molecular targeted therapy.

Number of accesses :  

Other information